KAZIA Shareholder Information Sessions June 2018

Sydney, 25 June 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite shareholders to attend information briefing sessions to discuss the company’s recent activities.


Kazia Therapeutics investor newsletter - May 2018

Kazia Therapeutics is pleased to make its May 2018 newsletter available to investors via this link.


Emerging oncology researcher says women lose out as ovarian cancer treatments lag

A prominent Australian oncology researcher says ovarian cancer patients are losing out as badly-needed funds and clinical attention is focused on more prominent – yet not as deadly – women’s diseases.


Dr James Garner speaks with CommSec re our GDC-0084 Phase II trial start

Kazia Therapeutics (KZA) CEO, Dr James Garner discusses the progress of the company’s two drugs that are in development to treat brain & ovarian cancer.


NDF Research Senior Analyst Stuart Roberts interviews Kazia Therapeutics CEO Dr James Garner as the GDC-0084 phase II trial launches in the US

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).


Novogen changes name to Kazia Therapeutics

CommSec's Tom Piotrowski talks with Kazia Executive Director and CEO Dr James Garner about our company name change to Kazia Therapeutics.


Novogen becomes Kazia Therapeutics

Australian biotechnology company, Novogen has announced that it will change its name to Kazia Therapeutics and that it will consolidate its share register, after the overwhelming majority of shareholders voted in favour of the proposed changes at the company's AGM held in Sydney last week.


CommSec Executive Series interviews CEO Dr James Garner on benefits of new business model for patients

CommSec's Tom Piotrowski speaks with Novogen Ltd (NRT) CEO & Executive Director, Dr James Garner about the company’s key milestones over the past 12 months and the clinical trials for its brain cancer treatment drug.


Dr James Garner, CEO, speaks to Canary Networks investment forum

Novogen (ASX: NRT), Chief Executive Officer & Executive Director Dr James Garner , gives an update on Novogen since coming on board in 2016.


CommSec interview re our new name, Kazia Therapeutics and our clinical trial progress

CommSec's Tom Piotrowski speaks with Kazia Therapeutics (KZA) CEO & Managing Director, Dr James Garner about the company’s recent name change from Novogen and progress of its ovarian cancer and brain cancer drug trials.


Sky News Interview – In-licensing of GDC-0084

Novogen Sky News Interview